We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
BiondVax Pharmaceuticals Ltd | NASDAQ:BVXV | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.36 | 1.23 | 1.38 | 0 | 01:00:00 |
1
|
NAMES OF REPORTING PERSONS
Daniel E. Stone
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
PF
|
||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL
PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2 ☐
Not Applicable
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
WITH: |
7
|
SOLE VOTING POWER
624,000
|
|
8
|
SHARED VOTING POWER
0
|
||
9
|
SOLE DISPOSITIVE POWER
624,000
|
||
10
|
SHARED DISPOSITIVE POWER
0
|
||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
624,000
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
NOT APPLICABLE
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
12.96%
|
||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
|
Item 1.
|
Security and Issuer
|
(a)
|
Title of Class of Securities:
|
(b)
|
Name of Issuer:
|
(c)
|
Address of Issuer’s Principal Executive Offices:
|
Item 2.
|
Identity and Background
|
(a)
|
Name of Reporting Person:
|
(b)
|
Principal Business Address:
|
(c)
|
Occupation, Employment and Other Information:
|
(d)
|
Criminal convictions:
|
(e)
|
Civil proceedings:
|
(f)
|
Citizenship:
|
Item 3.
|
Source and Amount of Funds or Other Consideration:
|
Item 4.
|
Purpose of Transaction
|
Item 5.
|
Interest in Securities of the Issuer:
|
(a)
|
Number of shares as to which the Reporting Person has:
|
(i)
|
Sole power to vote or to direct the vote: 624,000
|
(ii)
|
Shared power to vote or to direct the vote: 0
|
(iii)
|
Sole power to dispose or direct the disposition: 624,000
|
(iv)
|
Shared power to dispose or direct the disposition: 0
|
(v)
|
Aggregate amount of shares beneficially owned: 624,000
|
(vi)
|
Percent of class represented in Item (v) above: 12.96%
|
(b)
|
See (a).
|
(c)
|
Not applicable.
|
(d)
|
Not applicable.
|
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of
the Issuer:
|
Item 7.
|
Material to Be Filed as Exhibits:
|
Dated: March 12, 2024
|
/s/ Daniel E. Stone
Daniel E. Stone |
1 Year BiondVax Pharmaceuticals Chart |
1 Month BiondVax Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions